What is a regulatory strategy? And for that matter, what do people sometimes think is a regulatory strategy but isn’t? Those are the questions that today’s guest, Mike Drues, discusses as he begins his conversation with host John Speer, founder of Greenlight Guru. Mike is President of Vascular Sciences, an education, training, and consulting company that offers many services to medical device, pharmaceutical, and biotechnology companies. Listen to the episode to learn how Mike thinks about competitive regulatory strategy, delays in complying with regulation, and reimbursement and regulatory strategy. Some of the highlights of this episode include:What regulatory strategy is and what it isn’tWhy a good regulatory strategy is so importantWhat competitive regulatory strategy isThe mistake of focusing on only one companyHow the EU MDR is affecting regulatory strategyWhat causes delays in complying with regulationsThe industry record on post-market surveillanceReimbursement and regulatory strategyMemorable quotes from Mike Drues:“Let’s not forget my old friend, competitive regulatory strategy.” “It’s never too soon, in my opinion, to start thinking about regulatory strategy.” “As a general rule, we have done an abysmal job on post-market surveillance across the board.” “I consider this whole thing to be a poker game, in every sense of the word.” Links:Mike Drues LinkedIn How to Construct an Effective Regulatory Strategy  Jon Speer LinkedIn Greenlight Guru Academy MedTech Excellence Community Greenlight Guru